Pro Health Pharma is well established in the Swedish market since 2015 where Omnilax now is the market leader in the macrogol 4000 segment in Sweden1. We have a strong focus on international expansion and growth, both with new products as well as entering new markets with the current product portfolio. Besides direct sales in Sweden, Pro Health Pharma is active in Italy and Spain via license partners.
- IQVIA 1 year data, packages, w52 2021.
Growth and international expansion
Our main focus for growth is product launches in selected countries in Europe with favorable market conditions for macrogols. Our business model is to be the Marketing Authorization holder and partner with well-established companies with a strong position within the gastroenterology area in the local markets. Our partners drive all sales and marketing activities in their territories.